Podcasts about tumors

In this episode of the Greyhorn Pagans podcast, host StijnFawkes welcomes Nate "Anāez" Zeleznick, a master trainer in ancient martial arts and meditation. Nate shares his journey from being bullied in his youth to becoming a pioneer in the United States for a unique Indonesian martial art. He discusses his personal transformation, including overcoming a brain tumor through a combination of ancient practices and modern science. Nate introduces his Integrated Ascension Method, a holistic approach to healing and personal growth, and shares insights on the power of breathwork and energy healing.TakeawaysNate Zeleznick's journey from bullying to mastery in martial arts.The power of breathwork and meditation in personal transformation.Overcoming a brain tumor with a holistic approach.Introduction to the Integrated Ascension Method.The significance of energy healing and its impact.Nate's experience with Indonesian martial arts and its uniqueness.The role of mindset in healing and personal growth.Insights into the ASCEND framework for holistic health.The importance of teachers and guides in personal development.Nate's vision for a world where everyone realizes their true potential.Join our Supporters Club:https://www.spreaker.com/podcast/greyhorn-pagans-podcast--6047518/supportFind Nate at:WebsitePure EnergyEmailGreyhorn Pagans:Support us on PatreonVisit our website for moreShow FireFae some love

Send us a text Indpendent Artist: Anyhoo - Heavier.Instagram: www.instagram.com/anyhoo.xoxo/SocialsHosts: Peter Cabral: www.instagram.com/brisbane_north_photography/Nick Cabral: www.instagram.com/nickcabral37/Producer: Darryn Arndt: www.instagram.com/darrynarndt/Theme song: Braden Mutch: www.instagram.com/braden_mutch/Instagram:  www.instagram.com/justhitplaypodcast/Facebook: www.facebook.com/JusthitplaypodcastEmail: justhitplay7300@gmail.comwww.youtube.com/@justhitplaypodcastwww.instagram.com/justhitplaypodcast/

One of the most common dilemmas in urologic oncology: what do you do when a patient has T1 disease in both the bladder and the ureter? In the final episode of the 2025 NMIBC Creator Weekend™ series, Dr. Vignesh Packiam, Dr. Mark Tyson and Dr. Sarah Psutka share how they approach complex bladder cancer cases with upper tract involvement. --- This podcast is supported by: Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1 --- SYNPOSIS The doctors discuss complex bladder cancer cases, sequencing treatments for patients with dual ureteral and bladder T1 disease, the impact of cystectomy on quality of life, and the use of blue light cystoscopy and intravesical therapy. They also delve into the rise of bladder cancer in younger patients, considerations for low-grade intermediate-risk disease, and emerging therapeutic options. --- TIMESTAMPS 00:00 - Introduction05:52 - Upper Tract Positive Cytology Dilemma09:10 - Cystectomy Considerations15:55 - Developing Better Patient-Reported Outcomes20:26 - Challenges with New Therapeutics26:31 - Deescalating Treatment for Low-Grade Cancer33:29 - Closing Remarks --- RESOURCES CISTO Trialhttps://pubmed.ncbi.nlm.nih.gov/37980511/

Marty Makary explains how the FDA began after toxic chemicals in food caused deaths, how it grew to regulate 20 percent of the US economy, and what he has changed in his first eight months including removing artificial dyes, cutting red tape, adding AI, and rewriting the food pyramid.

Sometimes life sneaks up on you and you have no choice but to face the dark corners we wish we could avoid. My guest today, Christophe van Durme is facing an impossibly difficult challenge of brain cancer as a young father. When i met Chris and saw the way he was handling his prognosis and building a legacy for his family, I knew I had to bring him to you.Christophe talks through fear, multiple surgeries, paralysis, future plans that shifted overnight, and the quiet moments he holds onto anyway. It's steady, honest, and strangely clarifying. There's something about the way he speaks that pulls you closer to your own life instead of pushing you into dread.Christophe shares what it means to live with brain cancer while raising a young daughter, holding onto hope, and planning for a future he might not fully get to see. He breaks down the reality of navigating treatment, rebuilding his body, losing parts of his independence, and still choosing connection. He also talks about the private podcast he's recording for his child so she'll always know his voice. This conversation is unfiltered, grounded, and full of the kind of truth most people only reach for when everything else falls away.What You'll Learn:How a brain cancer survivor story can shift your perspective without sinking your hopeWhat day-to-day life actually looks like when you're living with brain cancerHow people find meaning inside fear, not after itWhat legacy looks like when you strip out ego, performance, and pressureWhy tiny human moments hold more weight than the big milestonesHow honesty creates connection even in the darkest circumstancesLinks & Resources:Christophe van Durme - LinkedInProfitivisime (nonprofit discussed)Allison's links:Instagram: https://www.instagram.com/allison__hareLinkedIn: https://www.linkedin.com/in/allisonhare/Website: https://allisonhare.comFree clarity call: https://go.allisonhare.com/45-min-callNotable Quotables:“The only choice we get is how awake we want to be while it's happening.” (01:20)“My goal is simple. Leave the planet in a better state than if I hadn't been here.” (15:05)“Life is better than no life.” (35:10)“Joy exists inside pain.” (57:30)“I fear not being there next week.” (49:59)Timestamps:00:00 — Why this story matters02:30 — The moment everything changed04:00 — Diagnosis at 1706:35 — Tumor quadruples in size09:50 — Awake brain surgery13:10 — Preparing to die20:30 — Emotional fallout and identity24:45 — A friend's philosophy that shifted everything28:58 — MRI the day after his daughter's birth32:40 — Paralysis and rebuilding35:37 — Why he still wanted kids39:34 — The private podcast for his daughter49:03 — Recovery, setbacks, and resilience49:59 — Fear, honesty, and what he still hopes for55:59 — Choosing a joyful funeral57:32 — A reminder about being aliveTips & Takeaways:Meaning shows up when you stop pretending you're fine.The smallest moments end up being the ones that matter. Be sure to rate, review, and follow this podcast on your player and also, connect with me IRL for more goodness and life-changing stuff.Schedule a FREE podcast clarity call with me - Your future audience is out there. Talk to them!Sign up for the free Reinvention Roadmap weekly emailAllisonHare.comFollow me on Instagram, LinkedIn, Facebook, and YouTube.DOWNLOAD the free podcast equipment guide- No guesswork, no google rabbit holes, start recording todayReb3l Dance Fitness - Try it at home! Free month with this link.Personal Brand - need help building yours? Schedule a call with me here and let's discuss.Feedback and Contact:: allison@allisonhare.com

Das Vertrauen von Frau J. in Ärztinnen und Ärzte war lange erschüttert. Ihr Mann hatte einen fortgeschrittenen Bauchspeicheldrüsen-Tumor. Er lehnte eine Chemotherapie im Krankenhaus ab. Der Arzt sagte, dann können sie nichts für ihn tun. «Wir wurden einfach fallengelassen.» Medikamentenfehler werden erfasst, vermeidbare psychische Verletzungen jedoch nicht. Und gelten dadurch als nicht existent. David Schwappach will diesen Teufelskreis mit seinem Forschungsprojekt über psychische Verletzungen in der Krebsbehandlung sichtbar machen und durchbrechen. Er ist Professor für Patientensicherheit am Institut für Sozial- und Präventivmedizin der Universität Bern. Er sagt: «Die Betroffenen verlieren das Vertrauen ins Gesundheitssystem, ziehen sich zurück, sind enttäuscht und wütend.» Sein Forschungsprojekt läuft bis 2027. Betroffene und Angehörige können sich melden: psych-harm.ispm@unibe.ch. Nur drei Monate nach der Diagnose starb der Mann von Frau J. in einem Hospiz. Dort fühlten sie sich gut betreut.

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠Paraneoplastic Effects of Tumors⁠⁠⁠⁠ from the Oncology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Dass er singen kann, entdeckt er, als er wieder sprechen lernen muss. Als Kind verliert James Vickery durch einen Tumor sein Gehör auf dem linken Ohr - und nach der Operation auch seine Stimme. (superfly.fm)

Sonja Koppitz, Judith Werner www.deutschlandfunkkultur.de, Plus Eins

When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first? Part two of the 2025 NSCLC Creator Weekend™ series focuses on a complex case involving a 75-year-old woman with a history of breast malignancy, presenting with new dyspnea and a large mass in the left lower lobe. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS Our mock tumor board consists of surgeons, medical oncologists, and radiation oncologists to deliberate and determine the best treatment plan. The specialists explore diagnostic and treatment options, including neoadjuvant chemoimmunotherapy, invasive mediastinal staging, and the potential for surgical resection or radiation therapy. --- TIMESTAMPS 00:00 - Introduction05:01 - Approach to Isolated Brain Metastasis09:09 - Radiation Therapy Considerations12:06 - Imaging and Follow-Up Strategies14:39 - Resectability and Surgical Decisions19:10 - Conclusion --- RESOURCES PACIFIC Clinical Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1709937

When standard therapy fails, it does not have to be the end of the road for high-risk bladder cancer patients. Modern treatments, biomarkers, and clinical studies have opened up new avenues for treating recurrent non-muscle invasive bladder cancer (NMIBC). The penultimate episode of the 2025 NMIBC Creator Weekend™ series features urologic oncologists Dr. Vignesh Packiam, Dr. Mark Tyson, and Dr. Sarah Psutka discussing how they navigate complex bladder cancer scenarios. --- This podcast is supported by: Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1 --- SYNPOSIS The doctors share treatment strategies, staging processes, and post-therapy patient management techniques. They address recurrent disease, approaches to different stages of cancer, the role of biomarkers in determining treatment paths, and considerations for both high-risk and intermediate-risk patients. Additionally, the episode touches on new treatments, clinical trials, and patient quality of life post-treatment. --- TIMESTAMPS 00:00 - Introduction02:08 - Case Study: Initial Patient Assessment04:59 - Surgical Considerations and Techniques10:22 - Managing Bladder Cancer Recurrence11:15 - Treatment Options and Clinical Trials15:12 - Advanced Treatment Strategies28:14 - Closing Remarks and Credits --- RESOURCES VISTA Trial https://abstracts.mirrorsmed.org/abstracts/vista-phase-3-trial-vicinium-epcam-targeted-pseudomonas-exotoxin-bcg-unresponsive-non BRIDGE Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10515442/ CORE-008 Trialhttps://www.sciencedirect.com/science/article/abs/pii/S1078143924010147 GAIN Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10176900/

[include file=get-in-itunes.html] Kate and I had another fun Free For All Friday Show which we hope you really enjoy. We talked about a ton of things and as always had a really great time. While sitting in our Relax Sauna I love to watch documentaries. I sit in there and sweat for 30 minutes each […] The post Liver Tumors, Baby Formula, GMO Foods, Listener Questions & Much More! appeared first on Extreme Health Radio.

Guest: Jun-ichi Abe, MD, PhD Cancer therapies can trigger both acute and chronic vascular effects, from treatment-induced hypertension to long-term atherosclerotic changes. Learn more as Dr. Jun-ichi Abe shares insights from his presentation at the 2025 American Heart Association Scientific Sessions. Dr. Abe is a Professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center in Houston.

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/   00:00:00 - Intro - New Formulas and Salves! 00:01:40 - Breast Tumor 00:15:40 - Healing Crisis 00:17:35 - New School Courses - Tinctures and More! 00:37:33 - Mast Cell Activation Syndrome (MCAS) - UTI - Eyebags 00:37:33 - Mast Cell Activation Syndrome (MCAS) - UTI - Eyebags I started my period at age 6 in 2002. I always wore face masks and still do,  because I think I look much older than a 29-year-old should.

Pathologen sind schrullige Typen, die im Tatort die Leichen aufschlitzen? Nicht vollkommen falsch, aber doch nur ein sehr kleiner Ausschnitt von dem, was Pathologen tatsächlich tun. Prof. Dr. Irina Berger ist Chefärztin der Pathologie am Klinikum Kassel. Sie versucht jeden Tag zu entschlüsseln, wie krankes Gewebe sich entwickelt, um mit diesem Wissen Tumore zu bekämpfen - und zwar passgenau für jeden Patienten.

Editor in Chief Cecelia E. Schmalbach, MD, MSc, is joined by senior author Rick Friedman, MD, PhD, and Associate Editor James G. Naples, MD, to discuss their findings in "Microsurgical Outcomes in 1000 Patients With Cerebellopontine Angle Tumors: A Comprehensive Cohort Analysis," which was published in the November 2025 issue of Otolaryngology–Head and Neck Surgery.  Click here to read the full article.

AI isn't just writing your emails anymore—it's reading your hormones and mapping your risk. In this episode, endocrinologist and longevity doctor Dr. Fady Hannah-Shmouni talks about full-body MRIs, cancer blood tests, muscle-driven longevity, HRT, and an at-home cortisol test called ELI. We explore where AI, wearables, and testing truly help women, and where they fuel anxiety, waste money, and dull intuition. We also get real about supplements, bad actors in wellness, and what actually matters if you want to stay strong and functional at 80+. Listen if you want a grounded roadmap for using data, testing, and hormone support to extend your healthspan—not just add more noise to your wellness life. WE TALK ABOUT:  06:00 - Why the future of prevention is continuous data, not yearly check-ups 09:15 - From bulky wearables to ingestibles and toilet sensors: where tracking is headed 13:25 - The $10 trillion wellness economy, influencer noise, and why most women feel lost 18:22 - The truth about supplements: Risks, contaminants, and the few "non-negotiables" 22:30 - Why you don't need 20 biohacks to live longer 28:00 - Tumor-cell blood tests, full-body MRI, and how to think about false positives 35:00 - Sick-care vs wellness: Why women are pushed into the wellness economy 38:05 - How ELI works: Instant saliva cortisol, AI, and a new "Fitbit for your stress" 44:15 - CRP, inflammation, and why a low score is a longevity superpower 48:10 - Muscle as a longevity organ and why women can't "Pilates only" forever 52:10 - Perimenopause, andropause, lost productivity, and why this decade is a wake-up call 57:30 - HRT and dementia/heart disease risk: What the newer evidence suggests SPONSORS: Join me in Costa Rica for Optimize Her, a 5-night luxury women's retreat in Costa Rica with yoga, healing rituals, and biohacking workshops—only 12 spots available. Feeling bloated, tired, or hormonally off? Try BiOptimizers — supplements that actually absorb and work for women's health. Get 15% off with code BIOHACKINGBRITTANY. RESOURCES: Free gift: Download my hormone-balancing, fertility-boosting chocolate recipe. Explore my luxury retreats and wellness events for women. Shop my faves: Check out my Amazon storefront for wellness essentials. ELI Health website and Instagram Dr. Fady Hannah-Shmouni's Instagram LET'S CONNECT: Instagram, TikTok, Facebook Shop my favorite health products Listen on Spotify, Apple Podcasts, YouTube Music

A doctor’s choice to walk beside patients through their hardest moments comes from a calling to serve with both skill and heart. Dr. Angela Coscio’s love for people led her from lab research to breast cancer specialization, where she witnesses courage every day. At St. Luke’s, she finds purpose in connecting deeply with patients, guiding them through treatment with compassion and individualized care. Her story reflects teamwork, devotion, and the belief that every medical decision should be a true partnership. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered Did Dr. Coscio always want to be a doctor? What path did Dr. Coscio take to become a physician? What is the role of an oncologist? How does Dr. Coscio deliver a cancer diagnosis? Why did Dr. Coscio choose oncology as her specialty? What happens at a tumor board? What does being in a comprehensive cancer center like St. Luke’s mean for patients? Are cancer treatment options personalized? How does Dr. Coscio address questions about treatment options, such as chemotherapy vs. hormone therapy? How important is the caregiver's role in cancer treatment and recovery? Does Dr. Coscio encourage second opinions? What advice does Dr. Coscio have for young women facing breast cancer? How does Dr. Coscio support patients in communicating and preparing for doctor appointments? Timestamped Overview 05:06 Interpreter Self-Doubt in Spanish 07:37 Collaborative Patient Care Discussion 10:24 St. Luke's: Team & Care 16:23 Connections in Cancer Care 19:39 Chemotherapy Decision Based on Science 20:45 Engineering Mindset Meets Oncology 25:08 Key Questions for Cancer AppointmentsSee omnystudio.com/listener for privacy information.

BUFFALO, NY – November 18, 2025 – A new #review was #published in Oncotarget (Volume 16) on November 14, 2025, titled “Mechanism of anticancer action of bifidobacterium: Insights from gut microbiota.” This review, led by first author Hoang Do and correspondent author Ashakumary Lakshmikuttyamma from Thomas Jefferson University, explores how bifidobacterium, a common probiotic found in the gut, may contribute to cancer prevention and therapy. By analyzing existing studies, the authors highlight the growing importance of gut health in cancer treatment and shed light on how bifidobacterium could complement standard cancer therapies. Bifidobacterium is widely known for promoting digestive health and is often included in fermented foods and dietary supplements. However, emerging evidence suggests it may also play a broader role in immune regulation and cancer defense. The review explains how certain strains of bifidobacterium may enhance the effectiveness of chemotherapy, radiation, and immunotherapy in cancers such as breast, lung, colorectal, and gastric cancers. According to the review, bifidobacterium influences cancer outcomes through several biological mechanisms. It helps regulate immune function by reducing inflammation and supporting the activity of immune cells that target tumors. For instance, strains like B. longum and B. breve have been shown to lower levels of harmful inflammatory markers and boost anti-inflammatory responses. These changes can make cancer treatments more effective while also reducing side effects. “Presence of Bifidobacterium breve in gut microbiota extended the median progression-free survival of NSCLC patients.” The review also discusses how bifidobacterium helps detoxify the body by breaking down cancer-causing compounds and limiting their ability to damage cells. In preclinical studies, the probiotic reduced the activity of enzymes that produce carcinogens and helped in converting food-based substances into cancer-fighting agents. Some strains were even found to suppress genes that promote tumor growth and increase molecules that trigger cancer cell death. The authors emphasize that diet plays a critical role in supporting the growth of bifidobacterium. Foods rich in dietary fiber, especially those containing inulin and oligosaccharides like garlic, onions, or leeks, can help increase its levels in the gut. This suggests that simple dietary changes could not only improve gut health but also support cancer prevention and treatment strategies. Although the review presents compelling evidence, the authors stress the need for more clinical trials to determine how different strains of bifidobacterium affect specific types of cancer. Personalized approaches may be necessary to match the right probiotic strains with individual treatment plans. As research continues to uncover the link between gut microbes and cancer, bifidobacterium stands out as a promising natural ally that could enhance the body's defenses and improve cancer treatment outcomes. DOI - https://doi.org/10.18632/oncotarget.28779 Correspondence to - Ashakumary Lakshmikuttyamma - axl025@jefferson.edu Abstract video - https://www.youtube.com/watch?v=KTWJDAN15lY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28779 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

David Marques ist gezwungen, vom Leben und seinen Liebsten Abschied zu nehmen. Seit einem Jahr lebt der 41-jährige Vater mit einem unheilbaren Tumor. Es bleiben ihm noch wenige Wochen oder Monate. Ein Gespräch übers Leben, Sterben und Abschied nehmen. «Abgesehen von der Krebsdiagnose hatte ich ein glückliches Leben», sagt er. Der Biologe folgte stets seinem Interesse für die Vogel- und Tierwelt. Dann kam die unheilbare Krebsdiagnose. Seit einem Jahr kämpft er mit Chemotherapien gegen «Alphonso» – so nennt die Familie den Krebs. Davids Sohn ist sechs Jahre alt. Von Anfang an sprachen die Eltern offen mit ihm über die Krankheit. «Bald bin ich wieder am Sternen putze», sagt David lächelnd. Im Focus erzählt er, wie er von seinem Kind und seinen Liebsten Abschied nimmt – und zugleich versucht, das Leben bis zuletzt bewusst zu gestalten. ______________________ Habt ihr Feedback, Fragen oder Wünsche? Wir freuen uns auf eure Nachrichten an focus@srf.ch – und wenn ihr euren Freund:innen und Kolleg:innen von uns erzählt. ______________________ «Focus» ist ein Podcast von SRF -Host: Donat Hofer (Insta @donat.hofer) -Angebotsverantwortung: Anita Richner _______________________ Das ist «Focus»: Ein Gast – eine Stunde. «Focus» ist der SRF-Talk, der Tiefe mit Leichtigkeit verbindet. Nirgends lernt man Persönlichkeiten besser kennen.

As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We're kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS They discuss the operation of tumor boards at their respective institutions, the impact of virtual meetings, optimal strategies for mediastinal staging, the management of early-stage lung cancer, and the emerging role of ablation therapy. The conversation dives into the complexities of treating patients with recurrence or metastatic disease, highlighting the importance of collaborative decision-making in navigating these challenging scenarios. The episode emphasizes the critical role of multidisciplinary tumor boards in providing informed, patient-centered care. --- TIMESTAMPS 00:00 - Introduction06:59 - Role of Pulmonologists in Tumor Boards12:08 - Importance of Tissue Diagnosis24:52 - Lung Cancer Screening and Stigma34:01 - Interventional Radiology and Biopsies46:21 - Challenges with Immunotherapy and Radiation53:44 - The Importance of Multidisciplinary Teams54:24 - Final Thoughts --- RESOURCES American Lung Association 2024 Datahttps://www.lung.org/getmedia/12020193-7fb3-46b8-8d78-0e5d9cd8f93c/SOLC-2024.pdf National Lung Screening Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1102873 Checkmate 816https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 PACIFIC Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1709937

Dr. Jay Lalezari, CEO of CytoDyn, is focused on solid tumor immunology, particularly in triple-negative breast cancer, where their lead drug, leronlimab, is showing significant long-term survival benefits.  This monoclonal antibody targets the CCR5 receptor, converting cold tumors into hot tumors and making them more susceptible to immunotherapy checkpoint inhibitors. Work with leronlimab for 20 years has demonstrated the potential for use in colorectal cancer as well as TNBC, and to vastly expand the patient population that could benefit from immunotherapy. Jay explains, "When I became CEO back in November of 2023, my first order of business was to figure out where CytoDyn should go with this intriguing monoclonal antibody called leronlimab that targets CCR5. And we looked at a number of indications, and by far and away, the data that we found in solid tumor oncology is clearly the place CytoDyn will go to create the most benefit for patients and the most benefit for our shareholders. We recently presented some data in triple-negative breast cancer that is truly remarkable and potentially paradigm-shifting in the world of solid tumor oncology."   "Over the years, it became clear that CCR5 was not just for the virus to get inside the cell, but was playing a key role in setting up the tumor microenvironment in a variety of solid tumors that were CCR5 positive. That included typically triple-negative breast cancer, colon cancer, prostate cancer, pancreatic cancer, sarcoma, glioblastoma, and the urothelial cancers in particular. So CCR5 helps the cancer set up a tumor microenvironment that helps it both build blood vessels to provide nourishment for the cancer and attract suppressor cells that keep the host immune system at bay."  #CytoDyn #Oncology #Leronlimab #TNBC #ColorectalCancer #CCR5 cytodyn.com Listen to the podcast here

Dr. Jay Lalezari, CEO of CytoDyn, is focused on solid tumor immunology, particularly in triple-negative breast cancer, where their lead drug, leronlimab, is showing significant long-term survival benefits.  This monoclonal antibody targets the CCR5 receptor, converting cold tumors into hot tumors and making them more susceptible to immunotherapy checkpoint inhibitors. Work with leronlimab for 20 years has demonstrated the potential for use in colorectal cancer as well as TNBC, and to vastly expand the patient population that could benefit from immunotherapy. Jay explains, "When I became CEO back in November of 2023, my first order of business was to figure out where CytoDyn should go with this intriguing monoclonal antibody called leronlimab that targets CCR5. And we looked at a number of indications, and by far and away, the data that we found in solid tumor oncology is clearly the place CytoDyn will go to create the most benefit for patients and the most benefit for our shareholders. We recently presented some data in triple-negative breast cancer that is truly remarkable and potentially paradigm-shifting in the world of solid tumor oncology."   "Over the years, it became clear that CCR5 was not just for the virus to get inside the cell, but was playing a key role in setting up the tumor microenvironment in a variety of solid tumors that were CCR5 positive. That included typically triple-negative breast cancer, colon cancer, prostate cancer, pancreatic cancer, sarcoma, glioblastoma, and the urothelial cancers in particular. So CCR5 helps the cancer set up a tumor microenvironment that helps it both build blood vessels to provide nourishment for the cancer and attract suppressor cells that keep the host immune system at bay."  #CytoDyn #Oncology #Leronlimab #TNBC #ColorectalCancer #CCR5 cytodyn.com Download the transcript here

Diese Low Budget Kurzfilmdoku von Anna Zhukovets & Karen Abel wurde zwischen 2021 ( Karen hatte gerade die Untersuchungsergebnisse bekommen 3 Jahre mit einem Medikament stabil zu sein) und 2022 ( mitten im 2. Progress, das heißt der Tumor und die Metastasierung breiten sich aufgrund der Resistenz gegenüber der Behandlung aus) gefilmt. Inzwischen hat Karen schon den 4. Progress hinter sich:Die Regisseurin, Editorin, Fotografin und Journalistin Anna Zhukovets (Geboren 1997 in Mariupol; Vita unter https://www.hff-muc.de/de_DE/studente... ) schafft es innerhalb eines Jahres das Leben einer Frau – die niemals aufgibt - mit dem Lungenkrebs einzufangen. Dabei unterstützt Karen Anna inhaltlich und auch kreativ im gesamten Filmprozess.Wissbegierde, Offenheit, Loyalität und eine unermüdliche Selbstarbeit: Das ist Karen Abel. Gerade im Dokumentarfilm lernt man von jedem Menschen etwas. Von Karen lerne ich, mich mehr in Dankbarkeit und Optimismus zu üben. Von Anfang an, lehnt Karen Mitleid ab. Mitgefühl statt Mitleid. Das wünscht sie sich. Offene Fragen statt Stille. Zuhören. Wie hört man empathisch zu? Wie wird man einem persönlichen Portrait gerecht? Indem ich mich als Filmemacherin zurücknehme. Nur so kann man zuhören. Lungenkrebs, das ist die Krankheit der Zukunft. Sie betrifft uns alle. Familie, Freunde und Partner: Die Stigmata des rauchenden alten Mannes hemmt oft einen offenen Diskurs. Und es stimmt nicht. Immer mehr junge Nicht- und Nie Raucher sind betroffen. Ein Film, der die Vorurteile über Lungenkrebs entkräftet. Und gleichzeitig sichtbar macht. Nämlich: Die Geschichte von Karens und Vesnas '' Wie Phönix aus der Asche'' soll sich der eigenen Lebenskraft und Endlichkeit nähern.''Wie Phönix aus der Asche'' ist eine Film-Odyssee. Anna Zhukovets und Karen Abel machen sich auf die Suche nach den Tiefen der Krebsforschung. Sprechen mit Experten und Betroffenen, ohne zu erahnen, dass es sich bei dieser Reise durch die Wissenschaft um die eigene Reflexion dreht. Um den Tod und das Leben. ''Wie Phönix aus der Asche'' ist eine Erzählung einer Frau, die scheinbar dem Tod geweiht ist. Und dennoch: Nicht aufhören will die bestehenden Regeln der Medizin zu hinterfragen. Die Geschichte von Karen Abel, sie zeigt, wie sehr es sich lohnt, zu hinterfragen. Nach anderen Wegen zu suchen. Die Geschichte trägt die Erkenntnis mit sich, dass die Krebsforschung mehr kann als nur Strahlen- und Chemotherapie. Für Karen Abel muss sie ganzheitlich sein. Sie muss den Menschen im Kern mitdenken. Dafür muss die Ärzte-Patient: innen-Kommunikation auf Augenhöhe bleiben.Chapters00:00 Der Weg zur Selbstakzeptanz02:38 Stigmatisierung und die Realität von Lungenkrebs06:11 Die Entstehung von Lungenkrebs08:45 Die Herausforderungen der Diagnose12:03 Die Bedeutung von Lebensqualität und Achtsamkeit14:49 Der Umgang mit dem Tod und die Rolle der Ärzte

Will Bridges https://www.imdb.com/name/nm2782297/ shares his method for making every meeting an opportunity. And he explains what he did that let him come from 10 years of working random jobs and trying to make shorts here and there, to becoming the newly discovered talent, suddenly writing for hit series like “Black Mirror” and “Stranger Things” as well as being a co-creator with Charlie Brooker.Matt and Oren get Will to open up about what he learned from "Shaun of the Dead" and how those filmmakers pitched. And they break down the process of showing decision-makers a concept and the steps needed to get them to truly understand what it will look like, feel like, and clearly see the audiences it will resonate with.If you're looking for ideas to improve how you direct actors, you too will get a lot from this episode. And Will goes into the secret of freeing up established actors to do their best work. And he's got some warnings about key mistakes many directors often make---Help our Patreon! https://www.patreon.com/JustShootItPodMatt's Endorsement: "Paprika" https://www.imdb.com/title/tt0851578Oren's Endorsement: Mike Birbiglia's "Working It Out" podcast https://www.podpage.com/mike-birbiglias-working-it-out/ and Za'atar spice https://en.wikipedia.org/wiki/Za'atarWill's Endorsement: "Tumor", the graphic novel https://en.wikipedia.org/wiki/Tumor_%28comics%29 Hosted on Acast. See acast.com/privacy for more information.

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ 00:00:00 - Intro - Foods - Dr. Morse History 00:18:05 - Tumors  00:29:58 - Reincarnation 00:18:05 - Tumors  I'm a 50 year old female, and have a lump in my breast and head.  00:29:58 - Reincarnation When our bodies pass and we come into a new body in our next life — does any of the work we did on the body in this lifetime, pass to the next?

Hi friends! So thankful to be back with you guys today :) In this episode , I answer some more of your questions! We talk about my pituitary tumor symptoms, how to start recovery, coping when it's dark and cold outside, and my thoughts on "full" ed recovery. I hope this episode brings you peace! I'm so thankful for you!GabbiXx

To Health With That! Podcast Season 5, Episode 5. Thank you so much to Tony for generously sharing his story - the full interview was fabulous and included much more than we could put in one podcast episode, so we broke it into two. In this episode, Tony continues to share with the idea of MTHFR being a rebirth, new information he has about a tumor and his concerns about folate and tumor growth, and questions about MTHFR and anesthesia.00:00 - Introduction00:43 - Manageable steps01:07 - Symptom tracking01:23 - Staying in control (or not).02:03 - MTHFR as a rebirth02:45 - tumor03:10 - folate and tumor growth04:40 - Do we get enough B12 from food06:15 - B12 and lithium rotate07:15 - MTHFR and detox09:42 - mental health struggles and folic acid10:31 - MTHFR and anesthesia11:11 - MTHFR and nitrous oxide and preparing for surgery12:32 - MTHFR and antibiotics13:33 - Building back good gut floraThanks so much for watching! I have so many other resources for you. Here is the full version of this interview: https://youtu.be/SZmHnyCKd8UIf you would like to tell your own MTHFR story, you can schedule with Dr. Amy here: ⁠https://calendly.com/amy-tohealthwiththat/new-meeting⁠Check out the website first for lots of FREE stuff:WEBSITE: https://tohealthwiththat.com/ You can now Pre-order the book MTHFR Easy: Get Healthy For Life. https://www.amazon.com/MTHFR-Get-Started-Guide-Healthy-ebook/dp/B0FLFCY1YQ/ref=sr_1_2?crid=3E616JJOYSA12&dib=eyJ2IjoiMSJ9.7WXbrOZ6vkAu5Ncg9lJLavpPvim_O1kOvqp3LTim_snTq6Gahvu-NhWvC1mZurA6.XnOpY_FYGI_DbfEx9NmEwRrSM2USTXkw_HTykBFrMtw&dib_tag=se&keywords=amy+neuzil&qid=1755710249&sprefix=amy+neuzil%2Caps%2C98&sr=8-2 Look for Kindle, audiobook, and paperback versions also to be released on October 24, 2025.GENETIC ROCKSTARS (an MTHFR, methylation, and genetics community): https://community.tohealthwiththat.comThis story was shared graciously and generously with permission to post on the podcast, Youtube, and in print if that happens in the future.

Ian shares a bit of absolutely unofficial medical advice that you should only follow if you want a laugh

It could be a bug bite. Or a harmless fatty lump. But it might be a mast cell tumor. In this episode of the VetFolio Voice podcast, we delve into mast cell tumors in dogs, including the unpredictable nature of these tumors, nuances around interpretation of cytology and histopathology reports, cytologic grading accuracy, and options for therapy including surgery, chemo, radiation and Stelfonta, an injectable mast cell tumor treatment for dogs. You'll learn about staging considerations and the role of newer prognostic panels as well as strategies for client communication about mast cell disease.

❣ Gratis 7 Tage Ernährungsplan nach Glykoplan: Hier klicken❣ Galactose: Hier klicken (✔ 10 % CODE: TAN34909)Die Datenlage ist klar: Zuckerarme oder zuckerfreie Ernährung mit wenig Kohlenhydraten und guten Fetten hilft immer, egal ob bei Alzheimer, Parkinson oder sogar Krebst. Dr. med. Kurt Mosetter zeigt auf, dass es mittlerweile 56 verschiedene Bezeichnungen für Zucker gibt und wie du dich ernähren kannst, sodass die Zellen und dein Körper sich selbst reparieren. Danke an @swissbiohealthkreuzlingen3586 für das herausragende Therapeutentreffen. ✨ Mehr Infos zu Dr. Kurt Mosetter: Kurts Homepage: https://www.myoreflex.de/Der Glycoplan: Hier klickenInhaltsverzeichnis: 00:00 Intro 02:36 DAS hemmt Tumorzellen? 07:12 Bioelektrische Felder steuern 09:48 Epigenetische Reparaturmechanismen 12:24 Natursubstanzen fördern Gesundheit✨ Mehr mr.broccoli: Blog YouTube Instagram Telegram-Community (für besonders brisante Themen) Newsletter▶▶▶ Meine 10 Favoriten für mehr Gesundheit

In this episode of SurgOnc Today, Mark Knab, Charles Vining, and Kelvin Allenson discuss how the anatomic location of duodenal adenocarcinoma—from the first to the fourth portion—fundamentally shapes surgical decision-making. Discussion highlights include criteria for pancreaticoduodenectomy versus segmental or limited resections, the role of margin status and lymphadenectomy, and evolving data guiding resection strategy for non-ampullary duodenal cancers. Designed for practicing surgical oncologists, this episode emphasizes operative judgment, outcomes data, and the balance between oncologic adequacy and surgical morbidity.

Shirts, long sleeves, and hoodies are back for a limited time! This batch has the podcast logo on the back and on the front is a simple name tag saying "Dental Technician". Be proud of what you do and show the WORLD that we exist. Shirts on sale until November 8, 2025. As always 100% of the profits go towards the Foundation For Dental Laboratory Technology (https://dentallabfoundation.org/)! https://www.bonfire.com/its-all-in-the-name160/ This week, Elvis and Barb cross the globe to chat with the legendary Marc Rondeau—a Sydney-based dental technician, educator, and yes, nightclub DJ. From being one of 30 accepted out of 300 applicants into Australia's only dental tech program, to running one of the country's top labs, Marc's journey is packed with hard work, humor, and heart. He shares how a near-fatal car accident—and the brain tumor it uncovered—completely reshaped his perspective on work-life balance, pushing him to give back through teaching and advocacy. Now the Vice President of the Australian Dental Technicians Association (https://www.australiandentaltechnicians.com.au/), Marc talks about the fight to keep technicians recognized, the shift from analog to CAD/CAM, and why he believes every tech should know how to “wax before they CAD.” * Dental Labs—The Ivoclar (https://www.ivoclar.com/en_us) Flash Sale Is On! * From November 3rd to 14th, Ivoclar is bringing you unbeatable deals on the equipment that will set your lab up for success in 2026. * Upgrade your mill, your furnace, or expand your workflow—and save big while doing it! * Plus, when you purchase a milling machine (https://www.ivoclar.com/en_us/products/product-list?page=1&limit=12&filters=%5B%7B%22id%22%3A%22professions%22%2C%22advancedFilter%22%3Afalse%2C%22values%22%3A%5B%22Lab%22%5D%7D%2C%7B%22id%22%3A%22categories%22%2C%22advancedFilter%22%3Afalse%2C%22value%22%3A%22Digital%20Equipment%22%7D%5D), you'll get delivery, installation, and training—all included. That means your lab will be production-ready from day one. * But hurry—these savings vanish after November 14th! * Contact your Ivoclar sales rep today and power up your lab for the year ahead. The right CAM software can completely transform your lab's workflow — and no one understands that better than FOLLOW-ME! Technology (https://www.follow-me-tech.com/), creators of hyperDENT (https://www.follow-me-tech.com/hyperdent/#product_overview). That's why Roland DGA (https://www.rolanddga.com/applications/dental-cad-cam) has partnered with FOLLOW-ME! North America to offer the Roland DGA x hyperDENT Bundle for their DWX-53D series mills. This collaboration gives labs optimized performance, smoother milling, and incredible efficiency gains — with some users reporting up to two hours saved per case cycle without sacrificing quality. And here's the best part: Roland is making this available to everyone through a hyperDENT trade-in promo for existing users. It's the perfect opportunity to upgrade your CAM and take full advantage of the technology you already have. Plus, Nowak Dental Supplies (https://www.nowakdental.com/) is participating in the promotion and adding an exclusive bonus for NOLA Lab Fest attendees: the Multiple Instances feature at no additional cost. Don't miss your chance to see the difference in person! Join Jordan Greenberg — the “hyperDENT dude” himself — at NOLA Lab Fest, November 7–8 (https://www.nolalabfest.com/), and discover how CAM can redefine what your Roland mill can do. Special Guest: Marc Rondeau.

Linktree: ⁠https://linktr.ee/Analytic⁠Join The Normandy For Additional Bonus Audio And Visual Content For All Things Nme+! Join Here: ⁠https://ow.ly/msoH50WCu0K⁠In this Notorious Mass Effect segment, Analytic Dreamz delivers a comprehensive analysis of Rosalía's groundbreaking 2025 single “Berghain” featuring Björk and Yves Tumor, the lead track from her upcoming album Lux, releasing November 7 via Sony Music. Clocking in at 3:26, the Nicolás Méndez-directed video amassed 3M+ YouTube views in 24 hours and 6M+ by October 29, hitting #2 globally on Trending while debuting Top 5 on Spotify Spain and trending in Germany, Iceland, and Latin America. Filmed across Berlin and Barcelona, the multilingual masterpiece in German, English, and Spanish blends organ, choir, synth bass, and London Symphony Orchestra strings conducted by Daníel Bjarnason. Analytic Dreamz dissects symbolic scenes—from Catholic iconography and a wounded heart jewel to Snow White animal motifs, a dissolving sugar cube nod to Kieslowski's Three Colors: Blue, and a white dove ascension signifying rebirth post-heartbreak with subtle Rauw Alejandro references like the fox and garnet medallion. Fashion highlights include archival Alexander McQueen Fall 2002 shredded dress, Spring 2003 rosary sandals, Givenchy Spring 1997 fringed top, and Balenciaga Spring 2004 cutout piece, curated by José Carayol to evoke holiness and reincarnation. Lux's 18-song, four-movement structure features collaborators Carminho, Estrella Morente, Silvia Pérez Cruz, and shifts from Motomami's urban edge to orchestral spirituality, with 300K+ pre-saves and 1.2M+ Instagram likes signaling massive impact. Analytic Dreamz explores lyrics like “Ich halte viele Dinge in meinem Herzen” and Björk's “divine intervention” bridge, positioning “Berghain” as Rosalía's boldest evolution yet.Support this podcast at — https://redcircle.com/analytic-dreamz-notorious-mass-effect/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Featuring an interview from Dr John Strickler, including the following topics: Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00) Potential use of MRD assays for patients with microsatellite instability (MSI)-high localized colorectal cancer or those with delayed progression or metastatic disease (16:09) Tumor-informed MRD assays under clinical development (20:36) Predictive role of ctDNA in Stage III colon cancer treated with celecoxib; effect of low-dose aspirin on response to celecoxib in patients with PI3K pathway alterations (24:19) Case: A man in his late 50s with resected Stage IIA colon cancer (30:06) Case: A woman in her late 40s with Lynch syndrome and MSI-H colon cancer with a solitary, small hepatic metastasis (34:57) MRD as a future clinical trial endpoint for solid tumors; increasing incidence of colorectal cancer in younger people (40:24) Antibody-drug conjugates in the treatment of colorectal cancer (45:13) Perspectives on promising areas of clinical research in colorectal cancer (48:23) CME information and select publications

In this episode of JCO PO Article Insights, host Dr. Jiasen He summarizes the article, "Somatic Mutation Profiles of Colorectal Cancer by Birth Cohort" by Gilad, et al published October 11, 2025. TRANSCRIPT Jiasen He: Hello, and welcome to the JCO Precision Oncology Article Insights. I am your host, Jiasen He, and today, we will be discussing the JCO Precision Oncology article, "Somatic Mutation Profiles of Colorectal Cancer by Birth Cohort," by Dr. Gilad and colleagues. Early-onset colorectal cancer is defined as colorectal cancer diagnosed before the age of 50. Several reports have suggested that early-onset colorectal cancer has unique characteristics. Compared with late-onset colorectal cancer, early-onset colorectal cancer cases are more commonly found in the distal colon or rectum, tend to be diagnosed at more advanced stages, and may display unfavorable histologic features. Although the overall incidence of colorectal cancer has declined in recent decades, the incidence of early-onset colorectal cancer continues to rise. This increase appears to be driven by birth cohort effects. The reasons behind this rise remain unclear but are likely multifactorial, involving changes in demographics, diet, lifestyle, environmental exposures, and genetic predisposition. At the same time, studies have shown conflicting results regarding whether there are differences in the mutation profiles between early-onset and late-onset colorectal cancer. Therefore, it is crucial to explore whether colorectal cancer somatic mutational landscape differs across birth cohorts, as this could provide important insight into generational shifts in colorectal cancer incidence. To address this question, the authors conducted a retrospective study to characterize the mutation spectrum of colorectal cancer across different birth cohorts. Consecutive colorectal cancer patients who underwent somatic next-generation sequencing at the University of Chicago pathology laboratory between 2015 and 2022 were retrospectively identified. Tumors were tested for 154 to 168 genes and categorized as either microsatellite stable or high according to established thresholds. Patients with hereditary cancer syndromes or inflammatory bowel disease were excluded. Participants were then grouped into birth cohorts by decades, as well as into two major groups: those born before 1960 and after 1960. Genes that were identified in at least 5% of the sample were selected and grouped into 10 canonical cancer signaling pathways. These genes and pathways were then included in the analysis to explore their association with colorectal cancer across different birth cohorts and age groups. A total of 369 patients were included in the study, with a median birth year of 1955 and a median age at colorectal cancer diagnosis of 62.9 years. 5.4% were identified as having microsatellite-high tumors. The median tumor mutational burden was 5 mutations per megabase for microsatellite-stable tumors and 57.7 mutations per megabase for microsatellite-high tumors. Patients with microsatellite-high tumors tended to have earlier birth years and were diagnosed at an older age. However, after adjusting for potential confounders, neither birth year nor age remained statistically significant. Similarly, after controlling for confounders, no significant associations were observed between birth year or age and mutation burden. In this cohort, APC, TP53, and KRAS were the most frequently mutated genes. No statistically significant differences in the prevalence of gene mutations were observed across birth cohorts. Correspondingly, the most affected signaling pathways were the Wnt, TP53, and (RTK)/RAS pathways. Similar to the gene-level finding, no significant differences in the prevalence of these pathways were identified among birth cohorts. When examining patients born before and after 1960, the authors found that the older birth cohorts were diagnosed at an older age and had higher tumor mutational burden. However, no significant differences were observed in any of the genes or pathways analyzed. Among microsatellite-stable tumors, 18.3% were classified as early-onset colorectal cancer, while 81.1% were late-onset colorectal cancer. Consistent with previous reports, early-onset colorectal cancers in this cohort were more likely to be left-sided and more common among more recent birth cohorts. However, no significant differences were identified in any of the examined genes or pathways when comparing early-onset to late-onset colorectal cancer. In this cohort, a higher prevalence of early-onset colorectal cancer was observed among more recent birth cohorts, consistent with previous reports. Still, no distinct mutational signature was identified between the early and late birth cohorts. The authors proposed that the lack of distinct mutational profile by age or birth cohort may be due to the limited number of key molecular pathways driving colorectal cancer. Although environmental exposures likely differ across generations, the downstream effects may have converged on similar biological mechanisms, leading to comparable somatic mutations across cohorts. Alternately, they proposed that the observed birth cohort differences in colorectal incidence may be driven by distinct mutation signatures, epigenetic alterations, or changes in the immune microenvironment rather than variations in canonical gene mutations. As the authors noted, given the retrospective nature of this study, its modest sample size, and the predominance of advanced-stage tumors, larger prospective studies are needed to validate these findings. In summary, this study found no significant differences in the mutational landscape of colorectal cancer across birth cohorts or age groups. The authors proposed that the generational shift in colorectal cancer incidence is unlikely to be driven by changes in the underlying tumor genomics. However, larger prospective studies are needed to validate these findings. Thank you for tuning in to JCO Precision Oncology Article Insights. Do not forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Are cats the forgotten patients in oncology? Dr. Sue Ettinger is back on the Purr Podcast to elaborate on cancer tests, treatments, and why cats deserve more. Why are clinical trials and funding so limited for cats? What is the next big leap in feline oncology? What is the best practice for early cancer detection in cats? Dr. Sue Cancer Vet joins our hosts, Dr. Susan Little and Dr. Jolle Kirpensteijn, live from WVC 2025 to tackle one of veterinary medicine's biggest questions: Why are cancer diagnostics and treatments for cats lagging behind dogs?Thanks for tuning in to the Purr Podcast with Dr. Susan and Dr. Jolle!If you enjoyed today's episode, don't forget to subscribe, rate, and leave us a review—it really helps other cat lovers and vet nerds find the show. Follow us on social media for behind-the-scenes stories, cat trivia, and the occasional bad pun. And remember: every day is better with cats, curiosity, and maybe just a little purring in the background. Until next time—stay curious, stay kind, and give your cats an extra chin scratch from us. The Purr Podcast – where feline medicine meets feline fun.

Dr. Brooke Britton discusses degranulation events—a scary potential when a dog has mast cell tumors. Learn what degranulation is, why it happens, and how it can affect your dog. Also: practical tips for managing symptoms, potential connections between allergies and cancer, and how to care for dogs with mast cell tumors. Topics Discussed: • What is a degranulation event? • How mast cell tumors cause degranulation • Symptoms dogs may experience during a degranulation event • The role of allergies and chronic inflammation in mast cell tumor risk • Medications and treatments to manage symptoms • Low-histamine diets and their role in comfort care • Tips for preventing future mast cell tumor growth • The importance of early detection and regular vet check-ups Your Voice Matters! If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Videos: https://www.youtube.com/watch?v=Al7jjCXVhuE https://www.youtube.com/watch?v=6eb4GrcH_f8 Related Links: Our article on mast cell tumors: https://www.dogcancer.com/articles/types-of-dog-cancer/mast-cell-tumors-in-dogs/ Chapters: 00:00 Introduction 01:15 What Are Mast Cell Tumors? 02:30 The Role of Mast Cells in Normal Immune Response04:00 What Happens During a Degranulation Event?06:45 Symptoms Dogs May Experience During Degranulation09:00 How Dogs Might Feel During Degranulation Events11:00 Stomach Upset and Ulcers in Dogs with Mast Cell Tumors13:00 The Link Between Allergies and Mast Cell Tumors16:00 Managing Allergies in Dogs to Reduce Risk18:30 Diet Considerations: Low-Histamine and Commercial Diets22:00 Medications for Degranulation Symptoms: Benadryl and Tagamet25:00 The Truth About Diet and Cancer Prevention27:30 Why Balanced Diets Are Key for Dogs with Cancer29:45 Closing Thoughts on Degranulation and Mast Cell Tumors34:00 Outro: Support and Resources for Dog Owners Get to know Dr. Brooke Britton: https://www.dogcancer.com/people/brooke-britton-dvm-dacvim-oncology/    For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Tumor components and immune response indicators can be found in cerebrospinal fluid, or CSF, when someone has a brain tumor, in a new test developed by Chetan Bettagowda, director of neurosurgery at Johns Hopkins and one of the test's developers.  … Cerebrospinal fluid may hold the keys to brain cancer identification and treatment, Elizabeth Tracey reports Read More »

In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.

This is a text-to-speech (TTS) AI reading of our most recent blog post: 6 Facts Every Clinician Needs to Know About Tumor Lysis Syndrome.https://www.pointofcaremedicine.com/blog-post/6-facts-every-clinician-needs-to-know-about-tumor-lysis-syndrome-2025Tumor Lysis Syndrome (NEJM, 2025)Bociek RG, Lunning M. Tumor Lysis Syndrome. N Engl J Med. 2025;393(11):1104-1116. doi:10.1056/NEJMra2300923‍Related ContentTumor Lysis Syndrome Admission Template

About the size of a BASEBALL!!!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BUFFALO, NY – October 20, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on October 16, 2025, titled “Widespread folate receptor expression in pediatric and adolescent solid tumors – opportunity for intraoperative visualization with the novel fluorescent agent pafolacianine.” In this study, led by first author Ashley C. Dodd from Ann & Robert H. Lurie Children's Hospital and corresponding author Timothy B. Lautz from the same institution and Northwestern University Feinberg School of Medicine, researchers discovered that folate receptor beta (FRβ) is widely expressed in various pediatric and adolescent solid tumors. This finding highlights FRβ as a promising target for improving the accuracy of tumor surgery using a fluorescent imaging agent known as pafolacianine. Pediatric cancers are often challenging to remove completely during surgery, particularly when tumors spread or form small metastases. Fluorescence-guided surgery is a method that helps surgeons better identify tumors during operations using special imaging dyes. However, commonly used dyes such as indocyanine green are not tumor-specific and rely on general features of blood vessel permeability, limiting their precision. In this study, researchers investigated the potential of pafolacianine, a next-generation dye that targets folate receptors, for pediatric use. Folate receptors are proteins commonly found on the surface of cancer cells. Pafolacianine is already FDA-approved for adults with ovarian and lung cancers due to its ability to bind these receptors and highlight tumors during surgery. The research team analyzed tissue samples from 13 young patients diagnosed with various cancers, including Wilms tumor, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, Ewing sarcoma, and neuroblastoma. The results showed that FRα was predominantly absent, whereas FRβ was present in 100% of the tumor samples. Notably, FRβ appeared both on the tumor cells and in the surrounding tumor microenvironment but showed little to no expression in normal tissue, making it an excellent candidate for targeted imaging. “In this study, we performed immunohistochemistry staining on slides obtained from a range of pediatric patients with solid tumors.” This consistent expression of FRβ in pediatric tumors is a significant and novel finding. Earlier studies primarily linked FRβ to immune cells called tumor-associated macrophages. This study reveals that FRβ is also expressed directly on tumor tissue, which could help surgeons better distinguish cancer from healthy tissue during procedures. Based on these results, the team has launched a clinical trial to evaluate pafolacianine in children undergoing surgery for metastatic lung tumors. If successful, this method could make pediatric cancer surgery safer and more effective. Overall, this study suggests that targeting FRβ with pafolacianine could serve as a tumor-agnostic imaging strategy, applicable across a wide range of pediatric solid tumors. This represents a potential advancement in real-time surgical imaging and a step forward in pediatric cancer care. DOI - https://doi.org/10.18632/oncotarget.28772 Correspondence to - Timothy B. Lautz - TLautz@luriechildrens.org Abstract video - https://www.youtube.com/watch?v=0its0QkOcwM Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Nuestro guía por la sanidad pública, el nefrólogo Borja Quiroga, nos conduce hasta Dani, el paciente con tumor de páncreas que ayudó a desvelar chatGPT. ¿Cómo puede la IA dar superpoderes a los médicos? Conversamos con un experto en la aplicación de la IA en la sanidad, el neurólogo y director de Savana Ignacio Hernández Medrano.

In this episode of Healthy Mind, Healthy Life, host Avik welcomes Riza August, who shares her inspiring journey of resilience and self-discovery following a brain tumor diagnosis. Riza discusses her decision to reclaim her life through an 1845-mile bike journey, the emotional and spiritual growth she experienced, and the importance of sharing her story to help others heal. The conversation emphasizes the power of perspective, the significance of taking small steps towards recovery, and the ongoing journey of personal transformation. Takeaways Riza made a conscious decision to live after her diagnosis. The bike journey was a spiritual testament to perseverance. Healing can be facilitated through sharing one's story. Vulnerability is a powerful form of medicine for the soul. Asking 'What can I do?' can shift one's perspective. Even small steps can lead to extraordinary outcomes. Riza's journey opened her up to new experiences and opportunities. Embracing change is essential for personal growth. Healing and growth are lifelong practices. We are all worthy of healing and transformation.   Chapters 00:00 Introduction to Riza's Journey 02:02 The Decision to Live 03:44 Reflecting on Life's Choices 05:23 The Spiritual Journey of Biking 06:49 Healing Through Sharing 09:51 Overcoming Limitations 12:19 Embracing Change and Growth 13:46 Continuing the Journey of Transformation   Watch Video: https://youtu.be/XHyzG1sC-ns    Reach Risa: Facebook: https://www.facebook.com/risa.august.unleashed/ Instagram: https://www.instagram.com/risaunleashed/ LinkedIn: www.linkedin.com/in/risa-august-9b130524a      Disclaimer: This video is for educational and informational purposes only. The views expressed are the personal opinions of the guest and do not reflect the views of the host or Healthy Mind By Avik™️. We do not intend to harm, defame, or discredit any person, organization, brand, product, country, or profession mentioned. All third-party media used remain the property of their respective owners and are used under fair use for informational purposes. By watching, you acknowledge and accept this disclaimer.   -----   Healthy Mind By Avik™️ is a global platform redefining mental health as a necessity, not a luxury. Born during the pandemic, it's become a sanctuary for healing, growth, and mindful living. Hosted by Avik Chakraborty storyteller, survivor, wellness advocate this channel shares powerful podcasts and soul-nurturing conversations on:   • Mental Health & Emotional Well-being • Mindfulness & Spiritual Growth • Holistic Healing & Conscious Living • Trauma Recovery & Self-Empowerment   With over 4,500+ episodes and 197.4K+ global listeners, join us as we unite voices, break stigma, and build a world where every story matters.  

Cats deserve cancer breakthroughs too! Dr. Sue Ettinger, DVM, DACVIM (Oncology), shares what's on the horizon for feline cancer testing in the next episode of the Purr Podcast. Known on social media as Dr. Sue Cancer Vet, she is an international speaker, author, & vlogger. She is a board-certified specialist in medical oncology. She received her veterinary training at Cornell University College of Veterinary Medicine. She completed her residency in medical oncology at the Animal Medical Center in NYC in 2003.Thanks for tuning in to the Purr Podcast with Dr. Susan and Dr. Jolle!If you enjoyed today's episode, don't forget to subscribe, rate, and leave us a review—it really helps other cat lovers and vet nerds find the show. Follow us on social media for behind-the-scenes stories, cat trivia, and the occasional bad pun. And remember: every day is better with cats, curiosity, and maybe just a little purring in the background. Until next time—stay curious, stay kind, and give your cats an extra chin scratch from us. The Purr Podcast – where feline medicine meets feline fun.

In this episode with Meagan Lindquist, you’ll discover the world of AHCC, a cultured mushroom extract with a remarkable range of health benefits. We explore its origins, patented culturing process in Japan, and what makes AHCC uniquely bioavailable compared to other mushroom supplements. Meagan shares her health journey, her experiences supporting patients, and her passion for spreading awareness about AHCC’s research-backed potential—from cancer and HPV to Lyme disease and overall immune function. The conversation highlights AHCC’s role as an immunomodulator, antioxidant, and anti-inflammatory compound, reviewing studies that demonstrate its benefits for general immune support and as complementary therapy for serious conditions, such as cancer and chronic infections. Practical topics include supplement quality, dosing, and how to find credible sources. By the end, you’ll have insights and actionable information to evaluate AHCC as part of a thoughtful, science-driven approach to immune optimization and integrative health. Meagan (Mimi) Lindquist (@mimi_themedicin) is the co-founder of The Medicin, alongside her husband Chase. Together, they provide high-quality mushroom products to the world. With her background as a clinical dental hygienist, nutrition guide, and AHCC educator, she has been helping others prevent disease for over 12 years. Now, Mimi is dedicated to sharing the benefits of Immune Intel AHCC, a mushroom product unlike any other, to as many people as possible. She hosts monthly live calls with Dr. Nathan Riley for women trying to clear HPV naturally using AHCC. In her words, it is her "life's passion to spread the word about how powerful it is." Full show notes: bengreenfieldlife.com/ahccpodcast Episode Sponsors: Organifi Shilajit Gummies: Harness the ancient power of pure Himalayan shilajit anytime you want with these convenient and tasty gummies. Get them now for 20% off at organifi.com/Ben. BlockBlueLight: BlockBlueLight BioLights are the only lights extensively tested and recommended by building biologist Brian Hoyer as truly flicker-free, ultra-low EMF, and circadian-friendly, with three modes (day, evening, night) that support natural rhythms and optimize sleep quality. Get 10% off your first order at blockbluelight.com/Ben (discount autoapplied at checkout). Fatty15: Fatty15 is on a mission to optimize your C15:0 levels and help you live healthier, longer. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/BEN and using code BEN at checkout. LVLUP Health: I trust and recommend LVLUP Health for your peptide needs as they third-party test every single batch of their peptides to ensure you’re getting exactly what you pay for and the results you’re after! Head over to bengreenfieldlife.com/lvluphealth and use code BEN15 for a special discount on their game-changing range of products. BiOptimizers Magnesium Breakthrough: The 7 essential forms of magnesium included in this full spectrum serving help you relax, unwind, and turn off your active brain after a long and stressful day so you can rest peacefully and wake up feeling refreshed, vibrant, and alert. Go to bioptimizers.com/ben and use code ben15 for 15% off any order.See omnystudio.com/listener for privacy information.

10-03-25 - New Update On Tumor Listener Gary His Wife Who Flew To See Him In Hospital - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The only way to follow up last week's milestone is with the rarest of the rare medical cases. Fun. — Support and sponsor this show! Venmo Tip Jar: @wellthatsinteresting Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@wellthatsinterestingpod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Bluesky: @wtipod Threads: @wellthatsinterestingpod Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@wti_pod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Listen on YouTube!! Oh, BTW. You're interesting. Email YOUR facts, stories, experiences... Nothing is too big or too small. I'll read it on the show: wellthatsinterestingpod@gmail.com WTI is a part of the Airwave Media podcast network! Visit AirwaveMedia.com to listen and subscribe to other incredible shows. Want to advertise your glorious product on WTI? Email me: wellthatsinterestingpod@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices